Potential role of daratumumab in the treatment of multiple myeloma

Multiple myeloma is the second most common hematologic malignancy in the US. Treatments utilizing alkylating agents, corticosteroids, proteasome inhibitors, and immunomodulatory drugs have resulted in significant survival benefits, however, despite the advances, relapse is inevitable. Decreased dept...

Descripción completa

Detalles Bibliográficos
Autores principales: Khagi, Yulian, Mark, Tomer M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069139/
https://www.ncbi.nlm.nih.gov/pubmed/24971019
http://dx.doi.org/10.2147/OTT.S49480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069139/
https://www.ncbi.nlm.nih.gov/pubmed/24971019
http://dx.doi.org/10.2147/OTT.S49480

Ejemplares similares